CY1125263T1 - Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa - Google Patents

Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa

Info

Publication number
CY1125263T1
CY1125263T1 CY20211100962T CY211100962T CY1125263T1 CY 1125263 T1 CY1125263 T1 CY 1125263T1 CY 20211100962 T CY20211100962 T CY 20211100962T CY 211100962 T CY211100962 T CY 211100962T CY 1125263 T1 CY1125263 T1 CY 1125263T1
Authority
CY
Cyprus
Prior art keywords
lpa
gene expression
rnai
compositions
methods
Prior art date
Application number
CY20211100962T
Other languages
English (en)
Inventor
Stacey MELQUIST
Steven Kanner
David B. Rozema
David L. Lewis
Lauren J ALMEIDA
Darren H. Wakefield
Vladimir S. Trubetskoy
Tao Pei
Zhen Li
Aaron ALMEIDA
Original Assignee
Arrowhead Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals, Inc. filed Critical Arrowhead Pharmaceuticals, Inc.
Publication of CY1125263T1 publication Critical patent/CY1125263T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Περιγράφονται παράγοντες παρεμβολής RNA (RNAi) και συζεύγματα παράγοντα RNAi για αναστολή της έκφρασης του γονιδίου (apo(a)) LPA. Περιγράφονται επίσης φαρμακευτικές συνθέσεις που αποτελούνται από έναν ή περισσότερους παράγοντες RNAi LPA προαιρετικά με μια ή περισσότερες πρόσθετες θεραπευτικές. Η αποδέσμευση των περιγραφέντων παραγόντων RNAi LPA σε ηπατικά κύτταρα in vivo παρέχει αναστολή της γονιδιακής έκφρασης LPA και θεραπευτική αγωγή καρδιαγγειακών και σχετιζόμενων με καρδιαγγειακά ασθενειών.
CY20211100962T 2015-10-01 2021-11-08 Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa CY1125263T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02
PCT/US2016/054729 WO2017059223A2 (en) 2015-10-01 2016-09-30 Compositions and methods for inhibiting gene expression of lpa

Publications (1)

Publication Number Publication Date
CY1125263T1 true CY1125263T1 (el) 2023-03-24

Family

ID=58424351

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100962T CY1125263T1 (el) 2015-10-01 2021-11-08 Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa

Country Status (37)

Country Link
US (3) US9932586B2 (el)
EP (2) EP4029941A1 (el)
JP (4) JP6991966B2 (el)
KR (1) KR20180052703A (el)
CN (1) CN108368506A (el)
AU (2) AU2016331084B2 (el)
BR (1) BR112018006489A2 (el)
CA (1) CA3000397A1 (el)
CL (1) CL2018000803A1 (el)
CO (1) CO2018003678A2 (el)
CR (1) CR20180231A (el)
CY (1) CY1125263T1 (el)
DK (1) DK3356529T3 (el)
EA (1) EA038478B1 (el)
ES (1) ES2896298T3 (el)
HK (1) HK1259063A1 (el)
HR (1) HRP20211410T1 (el)
HU (1) HUE055942T2 (el)
IL (3) IL300438A (el)
JO (2) JOP20210043A1 (el)
LT (1) LT3356529T (el)
MA (1) MA43347B1 (el)
MX (2) MX2018003833A (el)
MY (1) MY195796A (el)
PE (1) PE20181139A1 (el)
PH (1) PH12018500713A1 (el)
PL (1) PL3356529T3 (el)
PT (1) PT3356529T (el)
RS (1) RS62523B1 (el)
SG (1) SG10202008530TA (el)
SI (1) SI3356529T1 (el)
TN (1) TN2018000094A1 (el)
TW (2) TWI784934B (el)
UA (1) UA121998C2 (el)
UY (1) UY36926A (el)
WO (1) WO2017059223A2 (el)
ZA (1) ZA202106265B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
CN113797348A (zh) * 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体
JP6989521B2 (ja) 2016-09-02 2022-01-05 アローヘッド ファーマシューティカルズ インコーポレイテッド 標的化リガンド
WO2018185241A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
WO2019010274A1 (en) * 2017-07-06 2019-01-10 Arrowhead Pharmaceuticals, Inc. RNAI AGENTS OF INHIBITION OF ALPHA-ENAC GENE EXPRESSION AND METHODS OF USE
TN2020000039A1 (en) * 2017-09-11 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
SG11201912188RA (en) * 2017-09-14 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
AU2018352379A1 (en) * 2017-10-17 2020-06-04 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
EP3710586B1 (en) * 2017-11-13 2022-11-23 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of lpa in a cell
AU2019342117A1 (en) * 2018-09-19 2021-03-04 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13- (HSD17B13), compositions thereof, and methods of use
BR112021009213A2 (pt) * 2018-11-13 2021-08-10 Silence Therapeutics Gmbh ácidos nucleicos para inibição da expressão de lpa em uma célula
WO2021119034A1 (en) 2019-12-09 2021-06-17 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
AU2021320550A1 (en) * 2020-08-05 2023-02-16 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting
WO2022079221A1 (en) * 2020-10-16 2022-04-21 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
TW202233837A (zh) 2020-11-05 2022-09-01 美商安進公司 用靶向ＬＰＡ的ＲＮＡｉ構建體治療動脈粥樣硬化性心血管疾病之方法
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
JP2024500035A (ja) 2020-12-23 2024-01-04 アルゴノート アールエヌエー リミテッド 心血管疾患の治療
CN117836307A (zh) 2021-06-18 2024-04-05 弘景生物科技有限公司 功能化的n-乙酰基半乳糖胺核苷
EP4396193A1 (en) 2021-08-30 2024-07-10 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
CA3232191A1 (en) * 2021-09-18 2023-03-23 Chong Li Lpa inhibitor and use thereof
WO2023114746A1 (en) 2021-12-15 2023-06-22 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024032681A1 (zh) * 2022-08-11 2024-02-15 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2024151937A1 (en) * 2023-01-13 2024-07-18 Eli Lilly And Company Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same
WO2024210530A1 (en) * 2023-04-03 2024-10-10 Olix Pharmaceuticals, Inc. RNAi AGENTS TARGETING LPA GENE AND USE THEREOF

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
EP1159441B8 (en) 1999-03-10 2008-10-29 Marie Curie Cancer Care Delivery of nucleic acids and proteins to cells
CZ308053B6 (cs) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
JP5274461B2 (ja) * 2006-08-18 2013-08-28 アローヘッド リサーチ コーポレイション ポリヌクレオチドのインビボ送達のためのポリ結合体
US8513207B2 (en) 2008-12-18 2013-08-20 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
PT2539451E (pt) 2010-02-24 2016-03-28 Arrowhead Res Corp Composições para entrega de arnsi dirigida ao alvo
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
EP3192800A1 (en) 2010-12-17 2017-07-19 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
KR20130136494A (ko) 2010-12-29 2013-12-12 애로우헤드 리서치 코오포레이션 효소 민감성 결합을 갖는 Ｉｎ Ｖｉｖｏ 폴리뉴클레오티드 전달 컨쥬게이트
MX2014001971A (es) 2011-08-26 2014-03-31 Arrowhead Res Corp Polimeros de poli(vinilester) para suministro de acido nucleico in vivo.
PE20142362A1 (es) * 2011-11-18 2015-01-30 Alnylam Pharmaceuticals Inc Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112014004528A2 (pt) 2012-04-18 2019-09-24 Arrowhead Res Corp polímeros de poli(acrilato) para entrega de ácido nucleico in vivo
WO2013177468A2 (en) 2012-05-24 2013-11-28 Isis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
RU2686080C2 (ru) 2013-05-01 2019-04-24 Ионис Фармасьютикалз, Инк. Композиции и способы
US20160272970A1 (en) 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
CN114601845A (zh) 2015-05-29 2022-06-10 箭头药业股份有限公司 抑制Hif2α基因表达的组合物及方法
US10208307B2 (en) * 2015-07-31 2019-02-19 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
CN113797348A (zh) 2016-03-07 2021-12-17 箭头药业股份有限公司 用于治疗性化合物的靶向配体

Also Published As

Publication number Publication date
EP3356529B1 (en) 2021-08-25
TW201726918A (zh) 2017-08-01
EA201890864A1 (ru) 2018-09-28
TN2018000094A1 (en) 2019-07-08
JOP20160211B1 (ar) 2021-08-17
CR20180231A (es) 2018-05-31
TW202332769A (zh) 2023-08-16
US20170096665A1 (en) 2017-04-06
EP3356529A4 (en) 2019-09-04
LT3356529T (lt) 2021-12-27
PH12018500713A1 (en) 2018-10-15
MX2018003833A (es) 2018-06-18
NZ741086A (en) 2023-11-24
BR112018006489A2 (pt) 2018-10-09
PL3356529T3 (pl) 2021-12-20
ZA202106265B (en) 2023-08-30
DK3356529T3 (da) 2021-11-08
HK1259063A1 (zh) 2019-11-22
JP2022113835A (ja) 2022-08-04
HRP20211410T1 (hr) 2021-12-24
IL290566B2 (en) 2023-07-01
IL290566B1 (en) 2023-03-01
AU2022283623A1 (en) 2023-02-02
AU2016331084A1 (en) 2018-04-19
EA038478B1 (ru) 2021-09-03
CL2018000803A1 (es) 2018-08-31
HUE055942T2 (hu) 2022-01-28
MA43347A (fr) 2018-08-08
SG10202008530TA (en) 2020-10-29
WO2017059223A2 (en) 2017-04-06
WO2017059223A3 (en) 2017-05-11
JP6991966B2 (ja) 2022-02-03
US20200263179A1 (en) 2020-08-20
TWI784934B (zh) 2022-12-01
JP2018529732A (ja) 2018-10-11
MX2022013010A (es) 2022-11-09
CA3000397A1 (en) 2017-04-06
UA121998C2 (uk) 2020-08-25
KR20180052703A (ko) 2018-05-18
IL258333B (en) 2022-03-01
CO2018003678A2 (es) 2018-11-30
JP7116212B2 (ja) 2022-08-09
MY195796A (en) 2023-02-21
IL258333A (en) 2018-05-31
SI3356529T1 (sl) 2022-01-31
JP2021087459A (ja) 2021-06-10
PE20181139A1 (es) 2018-07-17
MA43347B1 (fr) 2021-11-30
RS62523B1 (sr) 2021-11-30
US20180195070A1 (en) 2018-07-12
EP4029941A1 (en) 2022-07-20
US9932586B2 (en) 2018-04-03
PT3356529T (pt) 2021-11-04
IL300438A (en) 2023-04-01
CN108368506A (zh) 2018-08-03
US10662427B2 (en) 2020-05-26
EP3356529A2 (en) 2018-08-08
AU2016331084B2 (en) 2022-09-08
ES2896298T3 (es) 2022-02-24
IL290566A (en) 2022-04-01
UY36926A (es) 2017-04-28
TWI836693B (zh) 2024-03-21
WO2017059223A9 (en) 2017-08-17
JP2024009262A (ja) 2024-01-19
JOP20210043A1 (ar) 2017-06-16
JP7442574B2 (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
CY1125263T1 (el) Συνθεσεις και μεθοδοι για την αναστολη γονιδιακης εκφρασης της lpa
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CL2019000090A1 (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2.
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
JOP20170161A1 (ar) عوامل RNAi للعدوى بفيروس التهاب الكبد ب
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
MX2017011422A (es) Composiciones y metodos para inhibir la expresion del gen del factor xii.
CY1123485T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια νοσων
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
BR112018071216A2 (pt) inibidores de bromodomínios
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
CY1124345T1 (el) Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι
PH12019502660A1 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
AR106227A1 (es) COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN GÉNICA DEL GEN DE LA APOLIPOPROTEÍNA APO(a) (LPA)
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ
AR117790A1 (es) AGENTES DE ARNi PARA INHIBIR LA EXPRESIÓN DE HIF-2 a (EPAS1), COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS
AR112754A1 (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO
JO3769B1 (ar) علاج RNAi لعدوى فيروس التهاب الكبد B